Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences clinical decision-making between treatment and active surveillance. The development of novel predictive biomarkers will help with risk stratification, and clinical decision-making, leading to a decrease in over or under-treatment of patients with prostate cancer. Here, we report that Trop2 is a prognostic tissue biomarker for clinically significant prostate cancer by utilizing the Canary Prostate Cancer Tissue Microarray (CPCTA) cohort composed of over 1100 patients from a multi-institutional study. We demonstrate that elevated Trop2 expression is correlated with worse clinical features including Gleason score, age, and pre-operative PSA levels. More importantly, we demonstrate that elevated Trop2 expression at radical prostatectomy predicts worse overall survival in men undergoing radical prostatectomy. Additionally, we detect shed Trop2 in urine from men with clinically significant prostate cancer. Our study identifies Trop2 as a novel tissue prognostic biomarker and a candidate non-invasive marker for prostate cancer.
Scientific reports. 2024 Jan 04*** epublish ***
Shiqin Liu, Sarah J Hawley, Christian A Kunder, En-Chi Hsu, Michelle Shen, Lennart Westphalen, Heidi Auman, Lisa F Newcomb, Daniel W Lin, Peter S Nelson, Ziding Feng, Maria S Tretiakova, Lawrence D True, Funda Vakar-Lopez, Peter R Carroll, Jeffry Simko, Martin E Gleave, Dean A Troyer, Jesse K McKenney, James D Brooks, Michael A Liss, Tanya Stoyanova
Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA., Canary Foundation, Woodside, CA, USA., Department of Pathology, Stanford University, Palo Alto, CA, USA., Department of Radiology, Stanford University, Palo Alto, CA, USA., Department of Urology, University of Washington, Seattle, WA, USA., Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA., Program of Biostatistics and Biomathematics, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA., Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA., Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Department of Pathology, Eastern Virginia Medical School, Norfolk, VA, USA., Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA., Department of Urology, Stanford University, Palo Alto, CA, USA., Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. ., Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA. .